The recent study indicates that using donor cells for CRISPR treatments could enable larger-scale production, potentially benefiting a significant number of autoimmune patients.
One patient reported improvement within days and the ability to return to work two weeks post-treatment, showcasing potential rapid benefits of newly developed CRISPR therapies.
The researchers noted that their findings highlight the safety and immune-modulating efficacy of off-the-shelf CAR-T cells, which could revolutionize treatment for severe autoimmune diseases.
This study could pave the way for more accessible CRISPR treatments for autoimmune conditions, reflecting a shift in how we approach these complex diseases.
Collection
[
|
...
]